Antidotes to exogenous neurotoxic agents

Details for Australian Patent Application No. 2007212452 (hide)

Owner Samaritan Pharmaceuticals, Inc. Georgetown University

Inventors Greeson, Janet; Lecanu, Laurent; Papadopoulos, Vassilios

Agent Pizzeys

Pub. Number AU-A-2007212452

PCT Pub. Number WO2007/092458

Priority 11/347,020 03.02.06 US

Filing date 5 February 2007

Wipo publication date 16 August 2007

International Classifications

A61K 31/495 (2006.01) - having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

A61K 31/661 (2006.01) - Phosphorus acids or esters thereof not having PC bonds, e.g. fosfosal, dichlorvos, malathion

A61K 31/662 (2006.01) - Phosphorus acids or esters thereof having PC bonds, e.g. foscarnet, trichlorfon

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 39/02 (2006.01) General protective or antinoxious agents

Event Publications

25 September 2008 PCT application entered the National Phase

  PCT publication WO2007/092458 Priority application(s): WO2007/092458

20 January 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007212473-Devices and methods for gastrointestinal stimulation

2007212447-IGF-IR antagonists as adjuvants for treatment of prostate cancer